Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

abbott laboratories - ABT

ABT

Close Chg Chg %
115.93 1.33 1.14%

Pre-Market

117.25

+1.33 (1.14%)

Volume: 5.56M

Last Updated:

Nov 21, 2024, 3:59 PM EDT

Trade Now

Company Overview: abbott laboratories - ABT

ABT Key Data

Open

$115.50

 Day Range

115.14 - 117.64

52 Week Range

99.71 - 121.63

 Market Cap

$201.08B

Shares Outstanding

1.73B

 Public Float

1.72B

Beta

0.72

 Rev. Per Employee

N/A

P/E Ratio

35.26

 EPS

$3.30

Yield

189.77%

 Dividend

$0.55

EX-DIVIDEND DATE

Oct 15, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

5.28M

  

ABT Performance

1 Week
 
 0.03%
 
1 Month
 
 1.50%
 
3 Months
 
 2.88%
 
1 Year
 
 12.70%
 
5 Years
 
 38.44%
 

ABT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 29
Full Ratings ➔

About abbott laboratories - ABT

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

ABT At a Glance

Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Phone 1-224-667-6100 Revenue 40.11B
Industry Medical Specialties Net Income 5.70B
Sector Health Technology Employees 114,000
Fiscal Year-end 12 / 2024
View SEC Filings

ABT Valuation

P/E Current 35.255
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 33.768
Price to Sales Ratio 4.80
Price to Book Ratio 4.944
Price to Cash Flow Ratio 26.513
Enterprise Value to EBITDA 20.803
Enterprise Value to Sales 5.02
Total Debt to Enterprise Value 0.079

ABT Efficiency

Revenue/Employee 351,833.333
Income Per Employee 50,008.772
Receivables Turnover 6.11
Total Asset Turnover 0.543

ABT Liquidity

Current Ratio 1.638
Quick Ratio 1.163
Cash Ratio 0.526

ABT Profitability

Gross Margin 49.956
Operating Margin 16.044
Pretax Margin 16.615
Net Margin 14.214
Return on Assets 7.722
Return on Equity 15.144
Return on Total Capital 10.465
Return on Invested Capital 10.828

ABT Capital Structure

Total Debt to Total Equity 41.119
Total Debt to Total Capital 29.138
Total Debt to Total Assets 21.68
Long-Term Debt to Equity 37.686
Long-Term Debt to Total Capital 26.705
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Abbott Laboratories - ABT

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
34.61B 43.08B 43.65B 40.11B
Sales Growth
+8.48% +24.47% +1.34% -8.12%
Cost of Goods Sold (COGS) incl D&A
17.23B 19.86B 21.33B 20.07B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.33B 3.54B 3.27B 3.24B
Depreciation
1.20B 1.49B 1.25B 1.28B
Amortization of Intangibles
2.13B 2.05B 2.01B 1.97B
COGS Growth
+13.28% +15.26% +7.40% -5.90%
Gross Income
17.38B 23.21B 22.32B 20.04B
Gross Income Growth
+4.10% +33.59% -3.84% -10.24%
Gross Profit Margin
+50.21% +53.89% +51.14% +49.96%
2020 2021 2022 2023 5-year trend
SG&A Expense
12.09B 14.01B 13.96B 13.60B
Research & Development
2.42B 2.74B 2.85B 2.72B
Other SG&A
9.67B 11.28B 11.11B 10.88B
SGA Growth
-0.13% +15.95% -0.38% -2.57%
Other Operating Expense
- - - -
-
Unusual Expense
151.00M 523.00M 209.00M 188.00M
EBIT after Unusual Expense
5.14B 8.68B 8.15B 6.25B
Non Operating Income/Expense
536.00M (56.00M) 468.00M 1.11B
Non-Operating Interest Income
46.00M 43.00M 183.00M 385.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
708.00M 410.00M 315.00M 698.00M
Interest Expense Growth
-13.45% -42.09% -23.17% +121.59%
Gross Interest Expense
708.00M 410.00M 315.00M 698.00M
Interest Capitalized
- - - -
-
Pretax Income
4.97B 8.21B 8.31B 6.66B
Pretax Income Growth
+21.85% +65.28% +1.16% -19.77%
Pretax Margin
+14.36% +19.06% +19.03% +16.61%
Income Tax
497.00M 1.14B 1.37B 941.00M
Income Tax - Current - Domestic
39.00M 859.00M 1.31B 528.00M
Income Tax - Current - Foreign
566.00M 790.00M 723.00M 874.00M
Income Tax - Deferred - Domestic
(18.00M) (355.00M) (610.00M) (382.00M)
Income Tax - Deferred - Foreign
(90.00M) (154.00M) (49.00M) (79.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
(22.00M) (29.00M) (28.00M) (22.00M)
Consolidated Net Income
4.45B 7.04B 6.91B 5.70B
Minority Interest Expense
- - - -
-
Net Income
4.45B 7.04B 6.91B 5.70B
Net Income Growth
+21.36% +58.28% -1.95% -17.44%
Net Margin Growth
+12.86% +16.35% +15.82% +14.21%
Extraordinaries & Discontinued Operations
- - - 24.00M
-
Discontinued Operations
- - - 24.00M
-
Net Income After Extraordinaries
4.47B 7.04B 6.91B 5.70B
Preferred Dividends
- - - -
-
Net Income Available to Common
4.47B 7.04B 6.91B 5.70B
EPS (Basic)
2.5228 3.9673 3.939 3.2764
EPS (Basic) Growth
+21.67% +57.26% -0.71% -16.82%
Basic Shares Outstanding
1.77B 1.77B 1.75B 1.74B
EPS (Diluted)
2.5045 3.9363 3.9144 3.2596
EPS (Diluted) Growth
+21.67% +57.17% -0.56% -16.73%
Diluted Shares Outstanding
1.79B 1.79B 1.76B 1.75B
EBITDA
8.62B 12.74B 11.63B 9.68B
EBITDA Growth
+13.32% +47.81% -8.71% -16.78%
EBITDA Margin
+24.90% +29.57% +26.64% +24.13%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 131.091
Number of Ratings 29 Current Quarters Estimate 1.342
FY Report Date 12 / 2024 Current Year's Estimate 4.675
Last Quarter’s Earnings 1.21 Median PE on CY Estimate N/A
Year Ago Earnings 4.44 Next Fiscal Year Estimate 5.161
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 22 16 24 24
Mean Estimate 1.34 1.11 4.67 5.16
High Estimates 1.37 1.20 4.70 5.26
Low Estimate 1.33 1.03 4.66 5.10
Coefficient of Variance 0.56 4.32 0.21 0.73

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 16 16 14
OVERWEIGHT 5 4 5
HOLD 8 9 8
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Abbott Laboratories - ABT

Date Name Shares Transaction Value
Jul 3, 2024 Michael F. Roman Director 4,009 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 John G. Stratton Director 10,895 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Louis H Morrone EXECUTIVE VICE PRESIDENT 62,143 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $103.91 per share 6,457,279.13
Jul 3, 2024 Louis H Morrone EXECUTIVE VICE PRESIDENT 62,699 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $103.91 per share 6,515,053.09
Jul 3, 2024 Paola Gonzalez Director 3,509 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Robert J. Alpern Director 9,754 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 15, 2024 Robert Emmett Funck EXECUTIVE VICE PRESIDENT 45,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Robert Emmett Funck EXECUTIVE VICE PRESIDENT 221,438 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $47 per share 10,407,586.00
May 15, 2024 Robert Emmett Funck EXECUTIVE VICE PRESIDENT 211,341 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.57 per share 22,099,928.37
May 9, 2024 Lisa D. Earnhardt EXECUTIVE VICE PRESIDENT 61,462 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $106.25 per share 6,530,337.50
May 6, 2024 Daniel J. Starks Director 5,277 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Daniel J. Starks Director 6,727,182 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 1, 2024 Darren W. McDew Director 8,757 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 1, 2024 Michelle A. Kumbier Director 14,079 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 1, 2024 Nancy McKinstry Director 6,850 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 1, 2024 Nancy McKinstry Director 37,089 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 1, 2024 Claire L. Babineaux-Fontenot Director 3,682 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 1, 2024 Michael G. O'Grady Director 3,682 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 1, 2024 Michael G. O'Grady Director 4,404 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 1, 2024 Sally E. Blount Director 35,023 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Abbott Laboratories in the News